Carmen Jerónimo is Group Leader of the Cancer Biology & Epigenetics Group and the Scientific Coordinator of the Biobank at the Portuguese Oncology Institute of Porto (IPO Porto). She is also Guest Associate Professor at the Department of Pathology and Molecular Genetics and the Director of the Master Course in Oncology of Abel Salazar Biomedical Sciences Institute - University of Porto.
She obtained her BSc in Biology (1994), MSc in Oncology (1998), PhD in Biomedical Sciences (2001) and Habilitation in Pathology and Molecular Genetics (2011) from the University of Porto. Her PhD project was carried out at Johns Hopkins University (JHU), Baltimore, USA under the auspices of the GABBA Program, working on prostate cancer genetic and epigenetic alterations. From 2002 until 2007, she was a Post-doctoral Fellow and Invited Researcher at IPO Porto, in collaboration with JHU, working on detection of neoplastic cells by DNA-based technology in clinical samples obtained from non-invasive or minimal invasive methods. In 2008 she established her independent group at IPO Porto, working on Cancer Biology and Epigenetics (FCT-2008 Science Program). Since 2014 she holds a tenured position as Assistant Researcher at the Research Center of IPO Porto.
Until now, she has supervised 8 PhD students (5 as co-supervisor) and 27 master students, as well as several undergraduate students. Presently she mentors 2 Junior Researchers, 1 Post-doctoral fellow, 3 PhD students and 4 Master students.
She has authored or co-authored more than 160 international scientific publications including four book chapters and several review articles (H-index 42; Scopus 7/2019). She has collaborated in a patent submission (Methods and biomarkers for detection of bladder cancer US 20130210011/ EP 2630261 A1/ WO 2012052844 A1).
Currently, she serves as Section Editor of Clinical Epigenetics and Associate Editor of International Journal of Molecular Sciences and BMC Cancer, and she is also MC member of COST Action European Epitranscriptomics Network- CA16120-EPITRAN and Board member of the Section of Urological Research (ESUR) of European Association of Urology (EAU).
Her research interests are focused on the characterization of the epigenome of tumor cells, and the identification of functional changes involved in cell epigenetic homeostasis breakdown of. In the context of Personalized Medicine, she is works in the development of new of cancer epigenetic biomarkers based in liquid biopsies as well as in the drug discovery based on the modulation of epigenetic aberrations. Owing to the relevance that Immuno-oncology has demonstrated in recent years, she is also investigating the epigenetic expression modulation of biomolecules involved in immune checkpoint regulation, aiming at the improvement of immunotherapeutic strategies by combination with epi-drugs. More recently, she started tackling the contribution of deregulated non-coding RNAs and its interaction with other epigenetic mechanisms in malignant transformation.